Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any mitochondrial complex III deficiency in which the cause of the disease is a mutation in the CYC1 gene.
Features include always present findings: Episodic ketoacidosis, Ketoacidosis, Vomiting, and Decreased activity of mitochondrial complex III and others; and common findings: Encephalopathy, Progressive neurologic deterioration, Failure to thrive, and Ptosis and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 3 | Vomiting, Acute hepatic failure, Elevated circulating hepatic transaminase concentration |
CYC1 encodes cytochrome c1 (325 aa). Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation. Highest expression in Muscle Skeletal (365.1 TPM) and Heart Left Ventricle (350.9 TPM).
Mitochondrial complex III deficiency nuclear type 6 is associated with mutations in the CYC1 gene on chromosome 8.
CYC1 is classified as a druggable target with score 0.0.
Genetic testing for CYC1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 12 always present features, 9 common features.
No clinical trials have been registered for mitochondrial complex III deficiency nuclear type 6.
8 publications have been identified in PubMed for mitochondrial complex III deficiency nuclear type 6. Research spans Case Report / Case Series (38%), Basic Science / Preclinical (38%), and Review / Meta-Analysis (25%).
Lan SC (2026). [PMID: 42091683](https://pubmed.ncbi.nlm.nih.gov/42091683/). *Neurol Sci*. [Case Report / Case Series]
Dou K (2026). [PMID: 41805567](https://pubmed.ncbi.nlm.nih.gov/41805567/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
Dong H (2025). [PMID: 39878121](https://pubmed.ncbi.nlm.nih.gov/39878121/). *Autophagy*. [Basic Science / Preclinical]
İpek R (2025). [PMID: 40014158](https://pubmed.ncbi.nlm.nih.gov/40014158/). *Neurogenetics*. [Case Report / Case Series]
Shi Y (2024). [PMID: 39554572](https://pubmed.ncbi.nlm.nih.gov/39554572/). *J Gastrointest Oncol*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 3:02 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Lab test results | 3 | Decreased activity of mitochondrial complex III, Increased circulating lactate concentration, Elevated circulating hepatic transaminase concentration |
Growth and development | 2 | Failure to thrive, Growth delay |
Brain and nerves | 1 | Encephalopathy |
Eyes | 1 | Ptosis |
Metabolism | 1 | Metabolic ketoacidosis |
Čunátová K (2024). [PMID: 39053894](https://pubmed.ncbi.nlm.nih.gov/39053894/). *J Inherit Metab Dis*. [Review / Meta-Analysis]
Tavasoli A (2024). [PMID: 38846886](https://pubmed.ncbi.nlm.nih.gov/38846886/). *Ann Med Surg (Lond)*. [Case Report / Case Series]